Compare AbbVie Inc (ABBV) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs OneSpan Inc — how do they compare? AbbVie Inc trades at $248.98 (market cap $441.94B), while OneSpan Inc trades at $16.25 (market cap $600.69M). The key difference: AbbVie Inc is far larger — about 735.7× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| ABBV | OSPN | |
|---|---|---|
Market Cap | $441.94B | $600.69M |
Sector | Health | Technology |
52-Week High | $263.58 | $16.78 |
52-Week Low | $197.38 | $10.15 |
Enterprise Value | $506.19B | $569.77M |
Dividend Yield | 2.77% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
OneSpan (OSPN) trades at $16.78, up 3.33% today, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a P/E of 9.25, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 revenue growth and raised full-year guidance, reflecting positive business momentum.
The outlook is positive, driven by earnings strength and strategic initiatives, but risks include competitive pressures and potential margin compression. With a consensus price target of $17.00 and 67% buy ratings, Wall Street sees modest upside from current levels amid overall solid financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
